乳腺癌患者的健康状态效用值在EORTC QLU-C10D与PROMIS偏好评分之间存在系统性差异
在柏林Charité大学医学中心乳腺癌中心门诊,于2018年6月至2021年4月期间,对291例治疗90天后的乳腺癌患者采集QLU-C10D与PROPr评分。QLU-C10D均值0.71(95%CI 0.69-0.74)与PROPr均值0.43(95%CI 0.41-0.46)存在系统性差异(差值0.28,95%CI 0.27-0.30),一致性一般(组内相关系数0.46,95%CI 0.32-0.57)。两量表在年龄、治疗、癌症分期、婚姻状况和教育等已知组间区分度相似,QLU-C10D存在相关天花板效应。
要点
- QLU-C10D均值0.71(95%CI 0.69-0.74)与PROPr均值0.43(95%CI 0.41-0.46)系统性相差0.28(95%CI 0.27-0.30)。
- 两量表一致性一般,组内相关系数0.46(95%CI 0.32-0.57),Pearson相关系数0.83(95%CI 0.79-0.86)。
- QLU-C10D存在相关天花板效应,两量表在已知组间区分度相似。
核心结论
- QLU-C10D与PROPr因效用模型不同而以不同方式测量健康状态效用值,二者选择应结合背景、人群、疾病和治疗。
研究设计与样本
- 在柏林Charité大学医学中心乳腺癌中心门诊,于2018年6月至2021年4月期间,对291例治疗90天后的乳腺癌患者采集QLU-C10D与PROPr评分。
- 评估两量表的收敛效度、已知组间效度、一致性以及天花板和地板效应。
主要发现
- QLU-C10D均值0.71(95%CI 0.69-0.74)与PROPr均值0.43(95%CI 0.41-0.46)存在系统性差异,差值0.28(95%CI 0.27-0.30)。
- 两量表一致性一般,组内相关系数0.46(95%CI 0.32-0.57);Pearson相关系数0.83(95%CI 0.79-0.86)。
- 两量表在年龄、治疗、癌症分期、婚姻状况和教育等已知组间区分度相似。
- QLU-C10D存在相关天花板效应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The EORTC Quality of Life Utility Core 10 Dimensions (QLU-C10D) and the Patient-Reported Outcome Measurement Information System Preference Score (PROPr) are new health state utility (HSU) scores for quality-adjusted life years in cost-effectiveness analyses. Both are expected to measure HSU more comprehensively than existing measures in cancer patients by including cancer-related health domains such as fatigue. The aim of this study is to compare both scores in a sample of breast cancer patients. METHODS: We collected QLU-C10D and PROPr from 291 patients 90 days after treatment in the outpatient clinic of the breast cancer center at Charité - University Medicine Berlin between June 2018 and April 2021. We assessed both scores' convergent and known-groups validity, agreement, and ceiling and floor effects. RESULTS: The mean QLU-C10D score [0.71, 95% confidence interval (CI) 0.69-0.74] and the mean PROPr score (0.43, 95% CI 0.41-0.46) differed systematically (0.28, 95% CI 0.27-0.30) and showed fair agreement (intraclass correlation coefficient 0.46, 95% CI 0.32-0.57). The Pearson correlation coefficient was 0.83 (95% CI 0.79-0.86). Both scores showed similar discrimination across known groups of age, treatment, cancer stage, marital status, and education. The QLU-C10D showed relevant ceiling effects. CONCLUSION: QLU-C10D and PROPr measure HSU differently as a result of different utility models. The choice between QLU-C10D and PROPr should be informed by context, population, disease, and treatment.
引用
- Klapproth CP, Fischer F, Rose M, et al. Health state utility differed systematically in breast cancer patients between the EORTC QLU-C10D and the PROMIS Preference Score. J Clin Epidemiol. 2022. PMID: 36162712. doi:10.1016/j.jclinepi.2022.09.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。